BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 27458164)

  • 21. CDC25A governs proliferation and differentiation of FLT3-ITD acute myeloid leukemia.
    Bertoli S; Boutzen H; David L; Larrue C; Vergez F; Fernandez-Vidal A; Yuan L; Hospital MA; Tamburini J; Demur C; Delabesse E; Saland E; Sarry JE; Galcera MO; Mansat-De Mas V; Didier C; Dozier C; Récher C; Manenti S
    Oncotarget; 2015 Nov; 6(35):38061-78. PubMed ID: 26515730
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Overexpression and constitutive activation of FLT3 induces STAT5 activation in primary acute myeloid leukemia blast cells.
    Spiekermann K; Bagrintseva K; Schwab R; Schmieja K; Hiddemann W
    Clin Cancer Res; 2003 Jun; 9(6):2140-50. PubMed ID: 12796379
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mechanisms of resistance against PKC412 in resistant FLT3-ITD positive human acute myeloid leukemia cells.
    Stölzel F; Steudel C; Oelschlägel U; Mohr B; Koch S; Ehninger G; Thiede C
    Ann Hematol; 2010 Jul; 89(7):653-62. PubMed ID: 20119833
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The antitumor compound triazoloacridinone C-1305 inhibits FLT3 kinase activity and potentiates apoptosis in mutant FLT3-ITD leukemia cells.
    Augustin E; Skwarska A; Weryszko A; Pelikant I; Sankowska E; Borowa-Mazgaj B
    Acta Pharmacol Sin; 2015 Mar; 36(3):385-99. PubMed ID: 25640477
    [TBL] [Abstract][Full Text] [Related]  

  • 25. NFATc1 as a therapeutic target in FLT3-ITD-positive AML.
    Metzelder SK; Michel C; von Bonin M; Rehberger M; Hessmann E; Inselmann S; Solovey M; Wang Y; Sohlbach K; Brendel C; Stiewe T; Charles J; Ten Haaf A; Ellenrieder V; Neubauer A; Gattenlöhner S; Bornhäuser M; Burchert A
    Leukemia; 2015 Jul; 29(7):1470-7. PubMed ID: 25976987
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The role of HOXB2 and HOXB3 in acute myeloid leukemia.
    Lindblad O; Chougule RA; Moharram SA; Kabir NN; Sun J; Kazi JU; Rönnstrand L
    Biochem Biophys Res Commun; 2015 Nov; 467(4):742-7. PubMed ID: 26482852
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Enhancing SHP-1 expression with 5-azacytidine may inhibit STAT3 activation and confer sensitivity in lestaurtinib (CEP-701)-resistant FLT3-ITD positive acute myeloid leukemia.
    Al-Jamal HA; Mat Jusoh SA; Hassan R; Johan MF
    BMC Cancer; 2015 Nov; 15():869. PubMed ID: 26547689
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Single-cell mass cytometry reveals intracellular survival/proliferative signaling in FLT3-ITD-mutated AML stem/progenitor cells.
    Han L; Qiu P; Zeng Z; Jorgensen JL; Mak DH; Burks JK; Schober W; McQueen TJ; Cortes J; Tanner SD; Roboz GJ; Kantarjian HM; Kornblau SM; Guzman ML; Andreeff M; Konopleva M
    Cytometry A; 2015 Apr; 87(4):346-56. PubMed ID: 25598437
    [TBL] [Abstract][Full Text] [Related]  

  • 29. FLT3-ITD and TLR9 use Bruton tyrosine kinase to activate distinct transcriptional programs mediating AML cell survival and proliferation.
    Oellerich T; Mohr S; Corso J; Beck J; Döbele C; Braun H; Cremer A; Münch S; Wicht J; Oellerich MF; Bug G; Bohnenberger H; Perske C; Schütz E; Urlaub H; Serve H
    Blood; 2015 Mar; 125(12):1936-47. PubMed ID: 25605370
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Fetal and neonatal hematopoietic progenitors are functionally and transcriptionally resistant to
    Porter SN; Cluster AS; Yang W; Busken KA; Patel RM; Ryoo J; Magee JA
    Elife; 2016 Nov; 5():. PubMed ID: 27879203
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Flt3-dependent transformation by inactivating c-Cbl mutations in AML.
    Sargin B; Choudhary C; Crosetto N; Schmidt MHH; Grundler R; Rensinghoff M; Thiessen C; Tickenbrock L; Schwäble J; Brandts C; August B; Koschmieder S; Bandi SR; Duyster J; Berdel WE; Müller-Tidow C; Dikic I; Serve H
    Blood; 2007 Aug; 110(3):1004-12. PubMed ID: 17446348
    [TBL] [Abstract][Full Text] [Related]  

  • 32. DOCK2 interacts with FLT3 and modulates the survival of FLT3-expressing leukemia cells.
    Wu M; Hamaker M; Li L; Small D; Duffield AS
    Leukemia; 2017 Mar; 31(3):688-696. PubMed ID: 27748370
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A role of Gab2 association in Flt3 ITD mediated Stat5 phosphorylation and cell survival.
    Masson K; Liu T; Khan R; Sun J; Rönnstrand L
    Br J Haematol; 2009 Jul; 146(2):193-202. PubMed ID: 19438505
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Features of Ras activation by a mislocalized oncogenic tyrosine kinase: FLT3 ITD signals through K-Ras at the plasma membrane of acute myeloid leukemia cells.
    Köthe S; Müller JP; Böhmer SA; Tschongov T; Fricke M; Koch S; Thiede C; Requardt RP; Rubio I; Böhmer FD
    J Cell Sci; 2013 Oct; 126(Pt 20):4746-55. PubMed ID: 23943874
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The tyrosine kinase CSK associates with FLT3 and c-Kit receptors and regulates downstream signaling.
    Kazi JU; Vaapil M; Agarwal S; Bracco E; Påhlman S; Rönnstrand L
    Cell Signal; 2013 Sep; 25(9):1852-60. PubMed ID: 23707526
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The FLT3-ITD mutation and the expression of its downstream signaling intermediates STAT5 and Pim-1 are positively correlated with CXCR4 expression in patients with acute myeloid leukemia.
    Cao T; Jiang N; Liao H; Shuai X; Su J; Zheng Q
    Sci Rep; 2019 Aug; 9(1):12209. PubMed ID: 31434952
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Suppressor of cytokine signaling 2 (SOCS2) associates with FLT3 and negatively regulates downstream signaling.
    Kazi JU; Rönnstrand L
    Mol Oncol; 2013 Jun; 7(3):693-703. PubMed ID: 23548639
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Integration of Hedgehog and mutant FLT3 signaling in myeloid leukemia.
    Lim Y; Gondek L; Li L; Wang Q; Ma H; Chang E; Huso DL; Foerster S; Marchionni L; McGovern K; Watkins DN; Peacock CD; Levis M; Smith BD; Merchant AA; Small D; Matsui W
    Sci Transl Med; 2015 Jun; 7(291):291ra96. PubMed ID: 26062848
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Targeting BTK for the treatment of FLT3-ITD mutated acute myeloid leukemia.
    Pillinger G; Abdul-Aziz A; Zaitseva L; Lawes M; MacEwan DJ; Bowles KM; Rushworth SA
    Sci Rep; 2015 Aug; 5():12949. PubMed ID: 26292723
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Signal transduction of oncogenic Flt3.
    Choudhary C; Müller-Tidow C; Berdel WE; Serve H
    Int J Hematol; 2005 Aug; 82(2):93-9. PubMed ID: 16146838
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.